The following pages link to Feng-shou Ko (Q2807713):
Displaying 25 items.
- Identification of potential longitudinal biomarkers under the accelerated failure time model in multivariate survival data (Q2807714) (← links)
- The Method to Identify a Biomarker and to Evaluate Its Efficiency for Survival by Using the Joint Model of the Accelerate Failure Time and Longitudinal Data (Q2815342) (← links)
- Comparisons of allocating sample size rationally into individual regions under heterogeneous effect size in a multiregional trial by a fixed effect model and a random effect model (Q2834658) (← links)
- A Design For Survival Studies: A Multi-regional Trial With Unrecognized Heterogeneity (Q2859283) (← links)
- Using the Score Test to Identify the Longitudinal Biomarker Considering Accelerate Failure Time Model with the Frailty in Survival Analysis (Q2890113) (← links)
- The Identification of Potential Longitudinal Biomarkers and Measurements of Effectiveness for Biomarkers as Surrogates in Multivariate Survival Data (Q2920068) (← links)
- Identification of Longitudinal Biomarkers in Survival Analysis for Competing Risks Data (Q2931542) (← links)
- Identification of longitudinal biomarkers for survival by a score test derived from a joint model of longitudinal and competing risks data (Q2953291) (← links)
- Detecting Outliers in Large Medical Records: Using a Frontier Model (Q3017881) (← links)
- Using Frailty Models to Identify the Longitudinal Biomarkers in Survival Analysis (Q3064066) (← links)
- A Statistical Issue About a Phase III Multi-regional Trial for the Survival Data under Accelerated Failure Time Model with Unrecognized Heterogeneity (Q3462389) (← links)
- Evaluate the relative efficiency of a targeted clinical trial design to an untargeted design under the issue of cost (Q4606473) (← links)
- Approaches to Allocate Sample Size Rationally Into Individual Regions for a Multi-regional Trial Under Heterogeneous Effect Size (Q4648653) (← links)
- Discussion on the issue of sample size determination for a targeted to an untargeted and to a mixed effect model-based clinical trial design (Q5036468) (← links)
- How the mechanism of missing data on longitudinal biomarkers influences the survival analysis (Q5078061) (← links)
- An approach to use of an adaptive procedure to clinical trials for molecularly heterogenous subject selection at interim (Q5085585) (← links)
- An alternate approach for sample size determination in a multi-regional trial (Q5085625) (← links)
- Application of trajectories from growth curve in identification of longitudinal biomarker for the multivariate survival data (Q5138544) (← links)
- An Approach to Determine Sample Size and to Allocate Sample Size for a Specific Region in a Multiregional Trial for Survival (Time-to-Event) Data under Accelerated Failure Time Model (Q5177593) (← links)
- Sample Size Determination for a Two-Sided Multiple Components Tolerance Interval (Q5177616) (← links)
- Sample Size Determination and Rational Partition for A Multi- Regional Trial for Survival (Time-To-Event) Data with Unrecognized Heterogeneity that Interacts with Treatment (Q5249204) (← links)
- Sample size determination for quality control process using a multiple components tolerance interval (Q5739181) (← links)
- The issue about sample size for survival analysis considering the interaction of unrecognized heterogeneity and treatment (Q5867748) (← links)
- An issue about the efficacy for the time-to-event outcome based on accelerated failure time model with interaction of unrecognized heterogeneity and main effect (Q5875253) (← links)
- Comparisons of a multi-regional trial for four or five regions by fixed effect model and random effect model about allocating sample size rationally into individual regions for a multi-regional trial (Q6067486) (← links)
